Addus HomeCare Clears Q3 Print With Street Still Divided

ADUS reported Q3 results on November 4 with the stock up 4.4% on the week to $126.55, leaving the analyst debate that defined the pre-earnings setup unchanged but now tested against an actual print.

The positioning story heading into the release was notable for its absence of conviction. Short interest edged up 8.3% over the week to 4.6% of the free float, reversing some of the month-long decline flagged in the earnings preview, but the lending market remains far from stressed. Availability is ample at roughly 1,011%, meaning more than ten shares are available to borrow for every one already shorted. Borrowing costs have eased to 0.35%, down 17% over the past week and near the low end of the past six weeks. The options market tells the same relaxed story: the put/call ratio of 0.15 is effectively flat to its 20-day average, a z-score of just 0.14. None of this suggests the Q3 print triggered any meaningful repositioning in the borrow or derivatives market.

The sharpest story remains between analysts rather than in the data. Barclays raised its price target to $101 from $96 this week while maintaining its Underweight rating, the fourth target revision from the same analyst in 2026 and each time the stock has traded well above the ceiling he has drawn. At $126.55, ADUS is 25% above Barclays' target, a gap that has persisted for months. The bulls are anchored by RBC Capital's $134 Outperform and Citizens' $142 Market Outperform, both citing the company's personal care franchise momentum and M&A optionality. B of A Securities sits in the middle after its September downgrade to Neutral at $125, essentially a hold at current levels. The consensus mean target at $134.92 implies about 6.6% further upside from here. Factor scores are mixed: earnings yield ranks in the 70th percentile and EV/EBIT in the 60th, but EPS momentum trails in the low 40s and the 12-month forward EPS growth outlook ranks just 34th, reflecting the bear case's concern about hospice and home health headwinds.

The bull case rests on personal care resilience. Management has pointed to 6.5% same-store revenue growth in the personal care segment, improving rate dynamics in Illinois and Indiana, and a balance sheet carrying $103 million in cash against $94 million in debt, leaving room for the kind of acquisitions that have driven the growth story. The bear case centres on concentration risk: more than 20% of revenue runs through the Illinois CCP, and the finalized Medicaid Access Rule, together with minimum-wage pressure, keeps margin compression a live risk. The hospice segment's performance relative to expectations has been a recurring point of contention, with visits in the home health division down 15% year-on-year in the most recent quarter.

On the ownership side, BlackRock added 335,205 shares in the quarter to September 30, lifting its reported stake to 18.7% of shares outstanding. Dimensional Fund Advisors added 91,036 shares over the same period. American Century built a meaningful position, adding 246,312 shares through August. The register reflects a broadly passive and growth-oriented institutional base with no activist on the 13D/G register. Insider data is stale beyond the 90-day window, with the most recent open-market activity from June reflecting small planned sales under a 10b5-1 programme rather than directional conviction.

One outlier worth noting is the retail attention signal. Wikipedia page views and ORTEX stock page traffic produced a z-score of 6.1 as of mid-October, an unusually high spike in retail interest relative to the stock's own 90-day baseline. That reading predated the earnings event and may partly explain the stock's 14% run into the print. Whether the attention persists or fades now that the event has passed is what to watch alongside the gap between the stock at $126.55 and Barclays' $101 ceiling.